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OBJECTIVES: Our aim was to compare the practice 
of homeopathic GPs with that of allopathic GPs.
METHODS: In a ﬁrst step, we collected data (consulting
patients, diagnosis-management, and drugs prescribed)
from the medical practices of homeopathic GPs (n = 149)
by carrying out a transverse descriptive study with a 
representative sample from the homeopathic GPs general
population. In a second step, for allopathic GPs (n = 314),
we used data from the MEDIPLUS database (IMS
HEALTH). Then, we compared patient-management by
homeopathic and allopathic GPs—in terms of patients
and drug prescriptions—for the diagnoses that included
more than 100 patients and that were comparable after
the comparability analysis we had performed. We used
the 9th International Classiﬁcation of Diseases to code
diagnoses. To take seasonality into account, each step of
the study was repeated on 3 days, at 3 different periods
of the year 2001 (winter, spring, and autumn). For each
day of data collection, homeopathic GPs were asked to
complete a questionnaire for each consulting patient, and
consultations made by allopathic GPs were taken from
the MEDIPLUS database. RESULTS: Homeopathic and
allopathic GPs were consulted by 12.6–13 and 12–13.3
patients per day respectively. They mainly managed
common diagnoses. Nine diagnoses were comparable for
the two populations of GPs. For these diagnoses, the 2
populations of patients were 55.6% homogeneous for the
criterion “sex”, 33.3% homogeneous for the criterion
“age”, and 22.2% homogeneous for the criteria “sex and
age”. Per diagnosis, homeopathic GPs mainly prescribed
homeopathic drugs (69–82%), most frequently pills and
doses (61–80%). Allopathic GPs almost exclusively pre-
scribed classic therapeutic classes of drugs (antibiotics,
psychotropics, etc). CONCLUSION: There is close simi-
larity between diagnoses and patients that homeopathic
and allopathic GPs manage, but considerable differences
between the drug-types they prescribe.
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OBJECTIVES: Prospective ‘real-world’ patient experi-
ence data is a highly acceptable form of data that can be
relevant to an individual clinician’s practice in deter-
mining the optimal patient proﬁle to achieve the most 
efﬁcacious results. This study was designed to assess the
real-world effectiveness of a sleeping medication and
provide the treating physician with self-reported data to
proﬁle optimal patients for treatment. METHODS: Self-
reported data about symptoms of transient insomnia and
symptom relief prior to and after using a sleeping med-
ication were collected from patients via telephone or the
Internet. Treating physicians enrolled all patients and
received individual patient reports. RESULTS: A total of
1,378 patients completed both surveys. Ages were 39%
<45 and 43% between 45 and 64, and 77% were female.
At baseline, 62% of patients reported having difﬁculty
sleeping >14 nights per month. Factors creating periods
of insomnia included stress (59%), depression/anxiety
(39%), travel (3%), and work-related issues (3%). The
most important quality in a sleeping medication was
reported to be absence of ‘grogginess’ the following day
(46%). The least important factor was sleeping through
the night (24%). However, 64% of patients reported fre-
quent/repeated waking as the type of sleep difﬁculty expe-
rienced prior to taking the new medication. The time
required to get to sleep (15 to 60 minutes) improved for
all study participants. With a statistical signiﬁcance of 
p < 0.001, reported symptoms of trouble falling asleep,
not feeling rested, feeling sleepy the next day, and trouble
functioning the next day were improved by 3 to 5 points
on a 10-point scale. CONCLUSIONS: Findings suggest
that the use of the study medication offers considerable
relief of key symptoms. The ﬁndings also provide the
practicing clinician with insights into the factors that
patients require in a sleeping medication and suggest that
effectiveness endpoints complement and even synergize
with efﬁcacy endpoints.
